ZoomInfo Named a Leader in Intent Data Providers for B2B by Independent Research Firm
ZoomInfo received the highest possible scores in the collection methodologies, data security and compliance criteria
VANCOUVER, Wash., February 27, 2025--(BUSINESS WIRE)--ZoomInfo (NASDAQ: ZI), the Go-To-Market Intelligence platform, has been named a Leader in The Forrester Wave™: Intent Data Providers For B2B, Q1 2025.
The Forrester Wave™ is a guide for buyers considering their purchasing options in a technology marketplace and is based on analyst analysis and opinion. This ranking report provides a competitive positioning of technology providers, used as a starting point by end users who are evaluating technology to determine which vendors to 'short list' for further consideration in their own purchasing decisions.
The report recognized ZoomInfo with the highest scores possible across eight criteria, including Collection Methodologies, Identity Resolution, Data Security & Compliance, Future Proofing Data Collection, Insight Generation and Recommended Action, Data Integration & Delivery, Roadmap, and Partner Ecosystem. It also stated that "ZoomInfo offers strong intent capabilities across most industries."
"We believe being identified as a Leader by Forrester in B2B Intent – as well as Marketing & Sales Data – is recognition of ZoomInfo's momentum in innovation," ZoomInfo Chief Product Officer Dominik Facher said. "To us, this reflects our relentless innovation and dedication to providing actionable intelligence that empowers go-to-market teams to engage the right accounts and contacts at the right time, driving meaningful action and revenue growth. With the largest R&D investment among providers in this evaluation, we remain committed to future-proofing our solutions, ensuring compliance, and delivering the insights businesses need to succeed."
Strategy & Roadmap
The report says "ZoomInfo's strategy and roadmap are heavily focused on harnessing the emerging capabilities of AI for data collection, analysis, and activation. This impressive development plan is made possible through the largest R&D investment of any provider in this evaluation."
It also noted that "an extensive ecosystem of partners is a suitable complement to its strategic advantage as one of the most entrenched data providers in B2B."
Standout Capability: Diverse Set of Collection Methodologies
Additionally, the report states that for ZoomInfo, "a diverse set of collection methodologies is a standout capability, ranging from traditional web activity capture to collection from proprietary freemium software offerings and human outreach."
The report also cites that "In recent years, ZoomInfo has shown a focus on data compliance and future-proofing collection, while identity resolution and data integration are as advanced as you would expect from a top data company."
Access a copy of The 2025 Forrester Wave™ for B2B Intent to learn more.
Forrester does not endorse any company, product, brand, or service included in its research publications and does not advise any person to select the products or services of any company or brand based on the ratings included in such publications. Information is based on the best available resources. Opinions reflect judgment at the time and are subject to change. For more information, read about Forrester's objectivity here.
About ZoomInfo
ZoomInfo (NASDAQ: ZI) is the Go-To-Market Intelligence Platform that empowers businesses to grow faster with AI-ready insights, trusted data, and advanced automation. Its solutions provide more than 35,000 companies worldwide with a complete view of their customers, making every seller their best seller. ZoomInfo is a recognized leader in data privacy, with industry-leading GDPR and CCPA compliance and numerous data security and privacy certifications. For more information about how ZoomInfo can help businesses with go-to-market intelligence that accelerates revenue growth, please visit www.zoominfo.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250227614137/en/
Contacts
Media Contact: Rob MorseSenior Communications Managerpr@zoominfo.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
33 minutes ago
- Business Wire
MangoBoost Sets New Benchmark for Multi-Node LLM Training on AMD GPUs in MLPerf Training v5.0
BELLEVUE, Wash.--(BUSINESS WIRE)--MangoBoost, a provider of cutting-edge system solutions for maximizing compute efficiency and scalability, has validated the scalability and efficiency of large-scale AI training on AMD Instinct™ MI300X GPUs through its MLPerf Training v5.0 submission. Tailored for enterprise data centers prioritizing performance, flexibility, and cost-efficiency, this milestone demonstrates that state-of-the-art LLM training is now viable beyond traditional vendor-locked GPU platforms. This showcases how the AMD Instinct™ MI300X GPUs and ROCm™ software stack synergize with MangoBoost's LLMBoost™ AI Enterprise software and GPUBoost™ RoCEv2 NIC. Share Using 32 AMD Instinct™ MI300X GPUs across four nodes, MangoBoost fine-tuned the Llama2-70B-LoRA model in just 10.91 minutes, setting the fastest multi-node MLPerf benchmark on AMD GPUs to date. The system achieved near-linear scaling efficiency (95–100%), proving that MangoBoost's stack can support practical and scalable LLM training in production environments. Scalability and Efficiency for Enterprise Data Centers The result showcases more than just benchmark success—it underscores how enterprises can reliably scale LLM training across clusters without network bottlenecks or rigid infrastructure dependencies. Mango LLMBoost™: A full-featured MLOps software platform for large language models, supporting model parallelism, automatic tuning, batch scheduling, and advanced memory management. Mango GPUBoost™ RoCEv2 RDMA: Inter-GPU communication hardware optimized for low-latency, high-throughput node-to-node communication, sustaining line-rate performance across thousands of concurrent QPs. These technologies together deliver predictable and efficient multi-node training, ideal for organizations operating their own AI infrastructure or deploying on public cloud. Industry-First MLPerf Training on AMD MI300X GPUs This is the first-ever MLPerf Training submission on AMD GPUs spanning multiple nodes. MangoBoost's platform demonstrated robust performance with a 4-node, 32-GPU cluster and confirmed compatibility with additional model sizes and structures—including Llama2-7B and Llama3.1-8B—in internal benchmarks. These results validate the generalizability of MangoBoost's platform beyond benchmarks to diverse production-scale use cases. " I'm excited to see MangoBoost's first MLPerf Training results, pairing their LLMBoost AI Enterprise MLOps software with their RoCEv2-based GPUBoost DPU hardware to unlock the full power of AMD GPUs, demonstrated by their scalable performance from a single-node MI300X to 2- and 4-node MI300X results on Llama2-70B LoRA. Their results underscore that a well-optimized software stack is critical to fully harness the capabilities of modern AI accelerators." — David Kanter, Founder, Head of MLPerf, MLCommons Vendor-Neutral AI Infrastructure Enabled by AMD Collaboration The achievement was made possible through deep collaboration with AMD and seamless integration with the ROCm™ software ecosystem, enabling full utilization of MI300X's compute, memory bandwidth, and capacity. Enterprises are now empowered to choose infrastructure based on business needs—not vendor constraints. " We congratulate MangoBoost on their MLPerf 5.0 training results on AMD GPUs and are excited to continue our collaboration with them to unleash the full power of AMD GPUs. In this MLPerf Training submission, MangoBoost has achieved a key milestone in demonstrating training results on AMD GPUs across 4 nodes (32 GPUs). This showcases how the AMD Instinct™ MI300X GPUs and ROCm™ software stack synergize with MangoBoost's LLMBoost™ AI Enterprise software and GPUBoost™ RoCEv2 NIC." — Meena Arunachalam, Fellow, AI Performance Design Engineering, AMD "At MangoBoost, we've shown that software-hardware co-optimization enables scalable, efficient LLM training without vendor lock-in. Our MLPerf result is a key milestone proving our technology is ready for enterprise-scale AI training with superior efficiency and flexibility," said CEO Jangwoo Kim. MangoBoost continues to develop innovations in communication optimization, hybrid parallelism, topology-aware scheduling, and domain-specific acceleration to further scale performance in distributed AI workloads. About MangoBoost MangoBoost is a provider of cutting-edge, full-stack system solutions for maximizing compute efficiency and scalability. At the heart of the solutions is the MangoBoost Data Processing Unit (DPU), which ensures full compatibility with general-purpose GPUs, accelerators, and storage devices, enabling cost-efficient, standardized AI infrastructure. Founded in 2022 on a decade of research, MangoBoost is rapidly expanding its operations in the U.S., Canada, and Korea.
Yahoo
38 minutes ago
- Yahoo
QPS Celebrates 30th Anniversary
NEWARK, Del., June 04, 2025--(BUSINESS WIRE)--QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalytics and clinical trials, is celebrating its 30-year anniversary in 2025. Founded by Dr. Benjamin Chien in 1995 to provide high-quality bioanalytical liquid chromatography with tandem mass spectrometry (LC-MS/MS) contract services, QPS is now recognized as a global leader in contract research. Over the past 30 years, the company has grown from a single office in Delaware, USA to a widely respected, global, full-service CRO with 8 locations spread across the US, EU, Asia, India and Australia, a clinical trial network of over 700 sites and an increased focus on leveraging the power of AI to accelerate clinical trials. Over the years, QPS has grown from a small molecule bioanalysis shop of three people to a global CRO with more than 1,200 employees. "30 years is a major milestone for QPS and I couldn't be more proud of the hard-working and innovative people who choose to work at QPS. They are the backbone of the company, and I am very grateful for their valuable contributions," said founder and CEO of QPS, Dr. Benjamin Chien. "Through QPS, the pharmaceutical and biotechnology industries have access to dedicated, focused scientific expertise across the drug development spectrum. In facilities around the world, QPS has assembled best-in-class instruments, platforms, people and processes required to conduct the studies necessary to support client drug discovery and development programs focused on obesity, type 2 diabetes, oncology, CNS diseases, cell and gene therapy, and more," said Dr. Chien. Since its humble beginnings, QPS has expanded its service options, to include pharmacology, DMPK, toxicology, bioanalysis, translational medicine, leukopaks, PBMCs, cell therapy products, clinical trials, central lab services, and a full range of clinical research services. QPS is known for high-quality data, technical expertise, delivery of promised study timelines, collaborative solutions, and customer-focused strategies. Going forward, QPS plans to continue delivering custom-built research services that accelerate pharmaceutical breakthroughs across the globe. ABOUT QPS HOLDINGS, LLC QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,200+ employees in the US, Europe, Asia and Australia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, leukopaks, PBMCs and cell therapy products, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit or email info@ View source version on Contacts QPS CONTACT: Name: Gabrielle PastorePhone: 1-302-635-4290Email: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
43 minutes ago
- Business Wire
Law Offices of Frank R. Cruz Encourages Fortrea Holdings Inc. (FTRE) Investors To Inquire About Securities Fraud Class Action
LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Fortrea Holdings Inc. ('Fortrea' or the 'Company') (NASDAQ: FTRE) securities between , inclusive (the 'Class Period'). Fortrea investors have until August 1, 2025 to file a lead plaintiff motion. Law Offices of Frank R. Cruz Encourages Fortrea Holdings Inc. (FTRE) Investors To Inquire About Securities Fraud Class Action Share IF YOU SUFFERED A LOSS ON YOUR FORTREA HOLDINGS INC. (FTRE) INVESTMENTS, CLICK HERE TO SUBMIT A CLAIM TO POTENTIALLY RECOVER YOUR LOSSES IN THE ONGOING SECURITIES FRAUD LAWSUIT. You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at info@ by telephone at (310) 914-5007, or visit our website at What Happened? On September 25, 2024, the investment bank Jefferies downgraded Fortrea from buy to hold, citing perceived weaknesses in the Company's business model as a contract research organization ('CRO') amid pressure on biotechnology funding and that the cost savings Fortrea expects to achieve by existing transition services agreements ('TSAs') are 'not as material as one might think.' On this news, Fortrea's stock price fell $2.73, or 12.3%, to close at $19.48 per share on September 25, 2024, thereby injuring investors. Then, on December 6, 2024, Baird Equity Research stated that '[g]iven our ongoing concerns around the sector, [Fortrea's] choppy history post spin, and lack of clarity on the abrupt communications course change, we cannot recommend an actionable investment (buy or sell)[.]' On this news, Fortrea's stock price fell $1.90, or 8.1%, to close at $21.67 per share on December 6, 2024. Then, on March 3, 2025, before the market opened, Fortrea announced financial results for the fourth quarter and full year 2024, revealing the Company had missed its previously announced guidance for revenue and adjusted EBITDA for the full year 2024. The Company's financial results revealed full year adjusted EBITDA of $202.5 million, well below the Company's previously announced guidance of $220 million to $240 million. The Company also revealed full year revenue of $2.696 billion, which missed previously announced guidance of $2.7 billion to $2.725 billion. The Company further revealed financial guidance for the full year 2025, which projected declines in revenue and adjusted EBITDA, with revenues of $2.450 billion to $2.550 billion and adjusted EBITDA in the range of $170 million to $200 million. Thomas Pike ('Pike'), the Company's then-Chief Executive Officer ('CEO'), explained that 'full-service work for projects from the pre-spin period,' 'have less revenue and less profitability' and 'post-spin work is not coming on fast enough to offset the pre-spin contract economics.' Pike further revealed 'this older versus newer mix issue will continue to negatively impact our financial performance during 2025.' On this news, Fortrea shares fell $3.47, or 25.1%, to close at $10.38 per share on March 3, 2025, thereby injuring investors further. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to the Company's 2025 earnings; (2) Fortrea overstated the cost savings it would likely achieve by exiting the TSAs; (3) as a result, the Company's previously announced EBITDA targets for 2025 were inflated; (4) accordingly, the viability of the Company's post-Spin-Off business model, as well as its business and/or financial prospects, were overstated; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased Fortrea securities, wish to learn more about this action, or have any questions concerning this announcement or your rights or interests with respect to these matters, please click HERE or contact us at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
